Literature DB >> 24739980

Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.

Issa Nébié1, Nick J Edwards2, Alfred B Tiono3, Katie J Ewer2, Guillaume S Sanou3, Issiaka Soulama3, Souleymane Sanon3, Amidou Diarra3, Jean Baptiste Yaro3, David Kangoye3, Egeruan B Imoukhuede4, Adrian V S Hill2, Sodiomon B Sirima3.   

Abstract

Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso). The low neutralizing antibody titers reported in both adults and children (median titers, 139.1 and 35.0, respectively) are encouraging for the potential use of ChAd63 as a malarial vaccine vector.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24739980      PMCID： PMC4054245          DOI： 10.1128/CVI.00723-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  19 in total

1.  Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.

Authors:  Jonatan Ersching; Malva I M Hernandez; Fabrizzio S Cezarotto; Jovino D S Ferreira; Amely B Martins; William M Switzer; Zhiquan Xiang; Hildegund C J Ertl; Carlos R Zanetti; Aguinaldo R Pinto
Journal:  Virology       Date:  2010-08-24       Impact factor: 3.616

2.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 3.  Pain-related modulation of the human motor cortex.

Authors:  Simona Farina; Michele Tinazzi; Domenica Le Pera; Massimiliano Valeriani
Journal:  Neurol Res       Date:  2003-03       Impact factor: 2.448

4.  Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.

Authors:  M Dudareva; L Andrews; S C Gilbert; P Bejon; K Marsh; J Mwacharo; O Kai; A Nicosia; A V S Hill
Journal:  Vaccine       Date:  2009-04-16       Impact factor: 3.641

5.  Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.

Authors:  Susanne H Sheehy; Christopher J A Duncan; Sean C Elias; Katharine A Collins; Katie J Ewer; Alexandra J Spencer; Andrew R Williams; Fenella D Halstead; Samuel E Moretz; Kazutoyo Miura; Christian Epp; Matthew D J Dicks; Ian D Poulton; Alison M Lawrie; Eleanor Berrie; Sarah Moyle; Carole A Long; Stefano Colloca; Riccardo Cortese; Sarah C Gilbert; Alfredo Nicosia; Adrian V S Hill; Simon J Draper
Journal:  Mol Ther       Date:  2011-08-23       Impact factor: 11.454

6.  Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Authors:  Stefano Colloca; Eleanor Barnes; Antonella Folgori; Virginia Ammendola; Stefania Capone; Agostino Cirillo; Loredana Siani; Mariarosaria Naddeo; Fabiana Grazioli; Maria Luisa Esposito; Maria Ambrosio; Angela Sparacino; Marta Bartiromo; Annalisa Meola; Kira Smith; Ayako Kurioka; Geraldine A O'Hara; Katie J Ewer; Nicholas Anagnostou; Carly Bliss; Adrian V S Hill; Cinzia Traboni; Paul Klenerman; Riccardo Cortese; Alfredo Nicosia
Journal:  Sci Transl Med       Date:  2012-01-04       Impact factor: 17.956

7.  Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

Authors:  Eleanor Barnes; Antonella Folgori; Stefania Capone; Leo Swadling; Stephen Aston; Ayako Kurioka; Joel Meyer; Rachel Huddart; Kira Smith; Rachel Townsend; Anthony Brown; Richard Antrobus; Virginia Ammendola; Mariarosaria Naddeo; Geraldine O'Hara; Chris Willberg; Abby Harrison; Fabiana Grazioli; Maria Luisa Esposito; Loredana Siani; Cinzia Traboni; Ye Oo; David Adams; Adrian Hill; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Paul Klenerman
Journal:  Sci Transl Med       Date:  2012-01-04       Impact factor: 17.956

8.  A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.

Authors:  Matthew D J Dicks; Alexandra J Spencer; Nick J Edwards; Göran Wadell; Kalifa Bojang; Sarah C Gilbert; Adrian V S Hill; Matthew G Cottingham
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

9.  Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.

Authors:  Geraldine A O'Hara; Christopher J A Duncan; Katie J Ewer; Katharine A Collins; Sean C Elias; Fenella D Halstead; Anna L Goodman; Nick J Edwards; Arturo Reyes-Sandoval; Prudence Bird; Rosalind Rowland; Susanne H Sheehy; Ian D Poulton; Claire Hutchings; Stephen Todryk; Laura Andrews; Antonella Folgori; Eleanor Berrie; Sarah Moyle; Alfredo Nicosia; Stefano Colloca; Riccardo Cortese; Loredana Siani; Alison M Lawrie; Sarah C Gilbert; Adrian V S Hill
Journal:  J Infect Dis       Date:  2012-01-24       Impact factor: 5.226

10.  Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.

Authors:  Katie J Ewer; Geraldine A O'Hara; Christopher J A Duncan; Katharine A Collins; Susanne H Sheehy; Arturo Reyes-Sandoval; Anna L Goodman; Nick J Edwards; Sean C Elias; Fenella D Halstead; Rhea J Longley; Rosalind Rowland; Ian D Poulton; Simon J Draper; Andrew M Blagborough; Eleanor Berrie; Sarah Moyle; Nicola Williams; Loredana Siani; Antonella Folgori; Stefano Colloca; Robert E Sinden; Alison M Lawrie; Riccardo Cortese; Sarah C Gilbert; Alfredo Nicosia; Adrian V S Hill
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919
View more
  7 in total

1.  Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Authors:  Victorine A Mensah; Aly Gueye; Magatte Ndiaye; Nick J Edwards; Danny Wright; Nicholas A Anagnostou; Massamba Syll; Amy Ndaw; Annie Abiola; Carly Bliss; Jules-François Gomis; Ines Petersen; Caroline Ogwang; Tandakha Dieye; Nicola K Viebig; Alison M Lawrie; Rachel Roberts; Alfredo Nicosia; Babacar Faye; Oumar Gaye; Odile Leroy; Egeruan B Imoukhuede; Katie J Ewer; Philip Bejon; Adrian V S Hill; Badara Cisse
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

2.  Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo.

Authors:  Richard Kiener; Markus Fleischmann; Christiane Schwegler; Zsolt Ruzsics; Christian Thirion; Silke Schrödel; Benedikt Asbach; Ralf Wagner
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

3.  Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model.

Authors:  Kunitaka Yoshida; Mitsuhiro Iyori; Andrew M Blagborough; Ahmed M Salman; Pawan Dulal; Katarzyna A Sala; Daisuke S Yamamoto; Shahid M Khan; Chris J Janse; Sumi Biswas; Tatsuya Yoshii; Yenni Yusuf; Masaharu Tokoro; Adrian V S Hill; Shigeto Yoshida
Journal:  Sci Rep       Date:  2018-03-01       Impact factor: 4.379

4.  First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.

Authors:  Alfred B Tiono; Issa Nébié; Nicholas Anagnostou; Aboubacar S Coulibaly; Georgina Bowyer; Erika Lam; Edith C Bougouma; Alphonse Ouedraogo; Jean Baptist B Yaro; Aïssata Barry; Rachel Roberts; Tommy Rampling; Carly Bliss; Susanne Hodgson; Alison Lawrie; Amidou Ouedraogo; Egeruan Babatunde Imoukhuede; Katie J Ewer; Nicola K Viebig; Amidou Diarra; Odile Leroy; Philip Bejon; Adrian V S Hill; Sodiomon B Sirima
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

Review 5.  Vector-based genetically modified vaccines: Exploiting Jenner's legacy.

Authors:  Bahar Ramezanpour; Ingrid Haan; Ab Osterhaus; Eric Claassen
Journal:  Vaccine       Date:  2016-10-28       Impact factor: 3.641

6.  Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Authors:  Domtila Kimani; Ya Jankey Jagne; Momodou Cox; Eva Kimani; Carly M Bliss; Evelyn Gitau; Caroline Ogwang; Muhammed O Afolabi; Georgina Bowyer; Katharine A Collins; Nick Edwards; Susanne H Hodgson; Christopher J A Duncan; Alexandra J Spencer; Miguel G Knight; Abdoulie Drammeh; Nicholas A Anagnostou; Eleanor Berrie; Sarah Moyle; Sarah C Gilbert; Peninah Soipei; Joseph Okebe; Stefano Colloca; Riccardo Cortese; Nicola K Viebig; Rachel Roberts; Alison M Lawrie; Alfredo Nicosia; Egeruan B Imoukhuede; Philip Bejon; Roma Chilengi; Kalifa Bojang; Katie L Flanagan; Adrian V S Hill; Britta C Urban; Katie J Ewer
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

Review 7.  Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.

Authors:  Coralie F Daussy; Noémie Pied; Harald Wodrich
Journal:  Viruses       Date:  2021-06-24       Impact factor: 5.048
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.